Pharma News

Vientumab is indicated for the treatment of locally advanced or metastatic uroepithelial carcinoma in adult patients who have previously received platinum-containing chemotherapy and programmed death receptor-1 or programmed death ligand-1 inhinitors.

Despite this challenge, the company's positive expectations for GLP-1 pharmaceutical contracts will provide strong support for future profit growth. At the close of trading, shares in Aspen Pharmacare slipped, falling 13.23 per cent to close at R213.60.

Pfizer recently announced that it has completed the acquisition of Seagen, which specializes in antibody drug coupling agents (ADCs), for $43 billion.

Pharmaceutical giant Mundipharma International, part of the world-renowned Sackler Family, has failed for the second time to find a suitable buyer for its China unit in an asset disposal process restarted this year.

The Indonesian president on Monday announced his country's intention to sign commercial contracts totaling $3.5 billion with African countries during the second Indonesia-Africa Forum in Bali.

Under the agreement, the two companies will jointly develop two small molecule therapies targeting long non-coding Rnas (lncrnas), with the aim of further strengthening Bayer's R&D pipeline in precision oncology.

On August 30, HUTCHMED officially announced that it had voluntarily withdrawn its marketing application for fuquinitinib for second-line gastric cancer.

UCB, a Belgian-based biopharmaceutical company, will sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and Abu Dhabi-based investment company Mubadala for US$680 million (about 4.843 billion yuan).

• UCB

On August 21, 2024, Hengrui Pharmaceutical announced its remarkable financial results: in the half year, the company's revenue reached 13.601 billion yuan, an increase of 21.78% over the same period last year;

The study was a double-blind, placebo-controlled trial that enrolled a large number of patients with AChR+, MuSK+, and/or LRP4+, who accounted for approximately 95% of the total number of patients with gMG.

On August 28, the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) of China announced on its official website that Sanofi's application for the marketing of Tilizumab injection has been officially accepted.

The interim analysis showed that the combination of Keytruda and stereotactic radiotherapy (SBRT) did not significantly improve event-free survival or overall survival in patients with stage I or II non-small cell lung cancer (NSCLC)

The National Health Supervision Agency made it clear that the above-mentioned products lacked scientific evidence to support their efficacy and were not registered for health, in violation of the relevant laws and regulations of Paraguay.

In the second quarter of 2024, Lilly showed strong growth momentum, with revenue of $20 billion in the first half of the year, up 31% year-on-year, net profit of $5.21 billion, up 68%, and full-year revenue guidance expected to increase by $3 billion.

The drug is indicated for adult patients regardless of whether they are heterozygotes or non-carriers of apolipoprotein E ε4 (ApoE ε4).

Kenvue, the maker of Tylenol, has won a class action lawsuit against U.S. consumers.

CBC Group and Abu Dhabi sovereign wealth fund Mubadala. The transaction amounts to $680 million (approximately 4.84 billion RMB).

Siemens Healthcare has agreed to acquire Novartis AG's diagnostics unit for $223.5 million, a move aimed at further strengthening its strength in cancer treatments.

On August 26, 2024, news of the suspension of Valling and Valga, the flu vaccines produced by Pasteur, a subsidiary of Sanofi, spread quickly on the Internet.

Eli Lilly, a well-known pharmaceutical company in the United States, has officially announced on its official website that it has launched a low-dose version of a weight loss drug called Zepbound.